Corneal stromal effects and profiles with deep femtosecond laser ablations

Article

Corneal stromal effects and profiles with deep femtosecond laser ablations

Femtosecond laser ablation of the deep corneal stroma is a viable alternative to microkeratome donor preparation for DSAEK and DALK, Dr. Donald Tan told delegates on Saturday.

“There are only minor differences in stromal keratocyte reaction and interface inflammation between microkerotame and the femtosecond laser seen in our in-vivo rabbit eye model of deep lamellar dissection,” said Dr. Tan.

He said the results of his collaboration with Mario Nubile and his team in Italy showed that femtosecond stromal bed quality, rim cut quality, and accuracy of depth can now exceed the microkeratome for quality and accuracy.

Dr. Tan showed delegates a series of remarkable scanning electron microscope (SEM) microscopy images that illustrated the extreme precision offered by femtosecond ablation using the 200khz.

Tan and Dr. Nubile are currently testing the 500khz Visumax (Zeiss Meditech), which promises greater performance.

He said that Femtosecond laser provides a much more predictable ablation depth and diameter and also that endothelial surfaces showed a normal morphology when cut 150 microns from Descemet’s Membrane.

In his discussion Dr. Tan explained that applanating lasers caused some distortion on the posterior surface. Turning his examination to curved interface lasers, he showed that even when suction was lost during surgery, the quality of the cut was not compromised. “We deliberately induced suction loss in a rabbit series to see what effect it would have on cut quality. We found that when suction is lost, if the ophthalmologist reapplies suction and continues with the procedure there is no difference discernable - pristine flap lifts, no double layers.” He also believes that modern forms of lamellar corneal transplantation are transforming the field of corneal transplantation today. “Microkeratome-assisted lamellar dissection using Automated Lamellar Therapeutic Keratoplasty (ALTK) to prepare the posterior donor lamella is the current gold standard,” he declared.

However, he conceded that there are problems, including flap-related complications, such as incomplete flaps, variable thickness and diameter of donor, stromal bed ridges and irregularities and lenticular effects, such as a thicker periphery.

He noted potential femtosecond advantages include ease of surgery, improved stromal bed quality, better accuracy in depth of ablation, better donor edge quality - no restriction to shape and edge profiles and better lenticule profiles. The disadvantages include cost and poor laser penetration of corneal scars. He concluded by saying that femtosecond laser assisted forms of DSEK and DALK are now on the horizon.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.